LGC has expanded its innovative portfolio of SARS-CoV-2 quality solutions with the release of AccuPlex™ SARS-CoV-2 in Synthetic Oral Fluid reference material.

The product is designed to support development and testing efforts around novel saliva-based SARS-CoV-2 diagnostics.  It serves as an ideal research tool for assay developers as well as a complete quality solution for clinical laboratories employing such tests.

LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process, quality solutions that challenge the entire PCR test procedure, making them the preferred alternative to infectious materials. AccuPlex SARS-CoV-2 in Synthetic Oral Fluid can be utilized for oral fluid-based diagnostic development, as well as for assay verification at installation and day-to-day performance monitoring.

Michael Sweatt, Executive Vice President, LGC Clinical Diagnostics Division, stated, “As the need for solutions for SARS-CoV-2 diagnostics evolves to include alternative sample types, we are pleased to offer innovative tools for both test manufacturers and clinical testing labs. This addition to our suite of AccuPlex SARS-CoV-2 quality solutions is just the latest innovation in our efforts to support novel diagnostics development and implementation in response to the COVID-19 pandemic.”

To learn more about AccuPlex SARS-CoV-2 in Synthetic Oral Fluid reference material, as well as the complete line of SARS-CoV-2 Quality Solutions, please visit the LGC SeraCare website.

Learn more about AccuPlex™

more news from LGC